Provided by Tiger Trade Technology Pte. Ltd.

Taysha Gene Therapies, Inc.

4.53
-0.0400-0.88%
Post-market: 4.530.00000.00%18:39 EST
Volume:4.30M
Turnover:19.54M
Market Cap:1.24B
PE:-13.49
High:4.61
Open:4.48
Low:4.45
Close:4.57
52wk High:6.02
52wk Low:1.05
Shares:273.92M
Float Shares:184.00M
Volume Ratio:2.80
T/O Rate:2.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3359
EPS(LYR):-0.3570
ROE:-64.93%
ROA:-25.70%
PB:5.67
PE(LYR):-12.69

Loading ...

Stock Track | Taysha Gene Therapies Soars 5.39% Pre-market on Positive Analyst Ratings and Q3 Results

Stock Track
·
Nov 05, 2025

Taysha Gene Therapies (TSHA) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Nov 05, 2025

Taysha Gene Therapies Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 05, 2025

Taysha Gene Therapies’ Earnings Call Highlights Progress and Challenges

TIPRANKS
·
Nov 05, 2025

Taysha Gene Therapies: Advancing REVEAL Study and Mitigating Regulatory Risks Earns Buy Rating

TIPRANKS
·
Nov 05, 2025

Stock Track | Taysha Gene Therapies Plummets 5.83% as Q3 Losses Widen and Company Files Mixed Shelf Offering

Stock Track
·
Nov 04, 2025

Taysha Gene Therapies Inc Files for Mixed Shelf- SEC Filing

THOMSON REUTERS
·
Nov 04, 2025

Taysha Gene Therapies files automatic mixed securities shelf

TIPRANKS
·
Nov 04, 2025

Earnings Flash (TSHA) Taysha Gene Therapies Posts Q3 Net Loss $0.09 a Share

MT Newswires Live
·
Nov 04, 2025

Taysha Gene Therapies Amends Sales Agreement, Expands Offering

TIPRANKS
·
Nov 04, 2025

Taysha Gene Therapies Inc - Terminates Sales Agreement With Leerink Partners - SEC Filing

THOMSON REUTERS
·
Nov 04, 2025

Taysha Gene Therapies Q3 net loss widens as R&D costs rise

Reuters
·
Nov 04, 2025

BRIEF-Taysha Gene Therapies Q3 Net Income USD -32.733 Million

Reuters
·
Nov 04, 2025

Taysha Gene Therapies Q3 Operating Income USD -34.024 Million

THOMSON REUTERS
·
Nov 04, 2025

Taysha Gene Therapies Q3 EPS USD -0.09

THOMSON REUTERS
·
Nov 04, 2025

Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Nov 04, 2025

Taysha Gene Therapies Q3 EPS $(0.09), Inline. Revenue $0. Cash And Equivalents $299.94M.

Benzinga
·
Nov 04, 2025

Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4

GlobeNewswire
·
Oct 28, 2025

Taysha Gene Therapies Inc : Raymond James Initiates Coverage With Strong Buy Rating; Price Target $13

THOMSON REUTERS
·
Oct 21, 2025

Taysha Gene Therapies initiated with a Strong Buy at Raymond James

TIPRANKS
·
Oct 21, 2025